RESET: Virtual Reality Software for Patients With Stroke

Sponsor
Universidad de Almeria (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06132399
Collaborator
Ministerio de Ciencia e Innovación, Spain (Other), European Union (Other)
81
4
3
18
20.3
1.1

Study Details

Study Description

Brief Summary

The goal os this clinical trial is to develop and validate a gamified, fully immersive, and stroke-specific virtual reality software to improve physical disability and quality of life in patients with stroke.

The main questions it aims to answer are:
  • To assess the effects of a gamified, fully immersive and stroke-specific virtual reality 10-week intervention combined with usual care rehabilitation, compared to usual care rehabilitation alone and in combination with a commercially available VR system, on disability in patients with stroke.

  • To assess the effects of a gamified, fully immersive and stroke-specific virtual reality intervention combined with usual care rehabilitation, compared to usual care rehabilitation alone and in combination with a commercially available virtual reality system, on quality of life, upper-body motor function, gross manual dexterity, handgrip strength, static and dynamic balance, and cognitive function in patients with stroke

Condition or Disease Intervention/Treatment Phase
  • Device: VIRTUAL REALITY GLASSES
N/A

Detailed Description

Stroke is the leading cause of long-term disability and ranks as the second most prevalent cause of mortality worldwide. According to data from the World Health Organization, since 2005, the global probability of a person experiencing a stroke has increased by 50 percent. It is expected that 1 in 4 individuals will face the risk of having a stroke in their lifetime. A stroke can result in significant loss of motor functions, communications abilities, weakness, or hemiparesis, leading to a diminished quality of life. Therefore, improving the rehabilitation process is evidently of paramount significance. Virtual reality has emerged as a novel strategy to improve neurological diseases; however, there is an absence of an immersive software designed specifically for stroke patients within a gamified environment. Therefore, the aim of RESET randomized controlled trial is to evaluate the effect of a gamified, fully immersive, and stroke-specific virtual reality software on disability in stroke patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
81 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Development and Validation of a Novel Virtual Reality Software for Improving Disability and Quality of Life in Patients With Stroke
Anticipated Study Start Date :
Apr 1, 2024
Anticipated Primary Completion Date :
Jun 1, 2025
Anticipated Study Completion Date :
Oct 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Commercial non-immersive virtual reality group (UC+CVR)

The UC+CVR group will use the Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan) gaming system with the games Sports. The participants will be requested to play a variety of games so as to work on different dimension of rehabilitation. Progression through the intervention will allow participants to choose some specific activities within the games

Device: VIRTUAL REALITY GLASSES
The RESET virtual reality software will be integrated into the PICO virtual reality glasses (Pico Interactive, San Francisco, US) by DYNAMICS. Virtual reality consists of simulated interactions with environments and events that are presented to the individual through technology. The virtual environments may mirror real world situations or represent controlled environments away from the real world.

Experimental: Gamified, fully immersive and stroke-specific virtual reality group (UC+RESET)

The RESET virtual reality software will be integrated in the PICO virtual reality glasses (Pico Interactive, San Francisco, US) and it will be based on tasks related to motor control, balance, rhythmic movements and cognitive speed.

Device: VIRTUAL REALITY GLASSES
The RESET virtual reality software will be integrated into the PICO virtual reality glasses (Pico Interactive, San Francisco, US) by DYNAMICS. Virtual reality consists of simulated interactions with environments and events that are presented to the individual through technology. The virtual environments may mirror real world situations or represent controlled environments away from the real world.

Active Comparator: Usual care

The usual care approach involves 3 session/week of 90 minutes of physical therapy and occupational therapy.

Device: VIRTUAL REALITY GLASSES
The RESET virtual reality software will be integrated into the PICO virtual reality glasses (Pico Interactive, San Francisco, US) by DYNAMICS. Virtual reality consists of simulated interactions with environments and events that are presented to the individual through technology. The virtual environments may mirror real world situations or represent controlled environments away from the real world.

Outcome Measures

Primary Outcome Measures

  1. Disability (The Barthel index) [Changes from baseline to weeks 13 and 26]

    An ordinal scale used to measure performance in activities of daily living. It consists of 10 common activities, with eight of them representing activities related to personal care and 2 related to mobility. These are assessed for independence/dependence and scored via an arbitrary weighting system- the index yields a total score out of 100 - the higher the score, the lower degree of disability.

Secondary Outcome Measures

  1. Quality of life (NEWSQOL) [Changes from baseline to weeks 13 and 26]

    The Newcastle Stroke-Specific Quality of Life Measure assess the specific health-related quality of life measure of 56 items grouped into 11 domains: feelings; ADL/self-care; cognition; mobility; emotion; sleep; interpersonal relationships; communication; pain/sensation; vision; and fatigue. Each item is rated in range 0 to 3, and they are not significant individually. The results of each domain are obtained by the sum of the scores of the items, and higher values indicate greater impact on quality of life.

  2. Upper extremity motor function (Fugl-Meyer assessment of Upper Extremity) [Changes from baseline to weeks 13 and 26]

    The test consists of 33 items that evaluate the movement, coordination and reflex action of the shoulder, elbow, forearm, wrist and hand. Each item is scored on a 3-point scale (0=cannot perform, 1=performs partially, 2=performs fully) and the total score ranges from a minimum of 0 (hemiplegia) to a maximum of 66 points.

  3. Gross manual dexterity (The Box and Block Test) [Changes from baseline to weeks 13 and 26]

    The participant is seated at a table, facing a rectangular box that is divided into two square compartments of equal dimension by means of a partition. A total of 150 colored, wooden cubes or blocks (2.5 cm) are placed in one compartment. The participant is instructed to move as many blocks as possible, one at a time, from one compartment to the other for 60 seconds. The score is the number of blocks moved from one compartment to the other during the trial time. The patient's hand must cross over the partition in order for a point to be given, and blocks that drop or bounce out of the second compartment onto the floor are still rewarded with a point. Multiple blocks carried over at the same time, count as a single point. Higher scores on the test indicate better gross manual dexterity.

  4. Handgrip strength [Changes from baseline to weeks 13 and 26]

    Digital dynamometry will be used to assess the muscular strength in kilograms of both the affected and non-affected upper extremities.Participants will execute the test three times with each hand and the best score will be used to calculate the average of the three repetitions. The non-paretic side will be used as a reference for the paretic side.

  5. Lower extremity function (Berg Balance Scale) [Changes from baseline to weeks 13 and 26]

    The Berg Balance Scale is a quantitative assessment of balance in older adults. The scale consists of 14 items requiring subjects to maintain positions or complete movement tasks (common to everyday life) of varying levels of difficulty. Items receive a score of 0-4 based on ability to meet the specific time and distance requirements of the test. 0 represents inability to complete the item and a 4 represents the ability to complete it independently.

  6. Lower extremity function (Time Up and Go test) [Changes from baseline to weeks 13 and 26]

    The Time Up and Go assesses the ability to perform sequential motor tasks relative to walking and turning. The test requires participants to stand up from a chair, walk a distance of 3 meters, turn around, walk back to the chair and seat by themselves in the minimum timeframe possible. The time taken to complete the test is registered.

  7. Cognitive function (global cognitive function) [Changes from baseline to weeks 13 and 26]

    Mini-Mental State Examination consists of 11 simple questions or tasks related to global cognitive function. Typically, these are grouped into 7 cognitive domains; orientation to time, orientation to place, registration of three words, attention and calculation, recall of 3 words, language, and visual construction. The total score ranges 0-30. Higher scores indicating better cognitive performance.

  8. Cognitive function (executive function) [Changes from baseline to weeks 13 and 26]

    The Trail-Making Test-B will be used to assess the executive function. Successful performance of this test requires letter and number recognition, mental flexibility, visual scanning, and motor function. The Part B of the test consists of 25 circles, 13 of them numbered 1 to 13 and, and 12 lettered A to L, randomly distributed over a page of paper. The participant is required to connect the circles with a pencil as quickly as possible, alternating between numbers and letters and taking both series in ascending sequence (i.e. 1, A, 2, B, 3, C…). The time taken to complete the task and the number of errors are recorded in seconds. Greater time indicates greater impairment. A maximum time of 5 minutes is typically allowed. Participants unable to complete Part B within 5 minutes are given a score of 300 seconds.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women and men with either an ischemic or hemorrhagic stroke

  • Stroke between the last 7 to 14 days

  • Functional independence before stroke (modified Rankin scale <3)

  • Paresis of the lower extremity, upper extremity, or both, with a score <3 on the "motor arm" item of the National Institutes of Health Stroke Scale (NIHSS) scale

  • Ability to stand upright independently or with assistance

  • Ability to understand basic instructions and to decide whether to sign informed consent

Exclusion Criteria:
  • Moderate-severe aphasia that precludes understanding the required tasks

  • Cognitive impairment that precludes cooperation with tasks

  • Serious behavioral problems or mental disorders

  • Lower extremity deep vein thrombosis, quadriplegia, neurodegenerative diseases, lower limb fractures, or recent myocardial infarction

  • Vital organ (heart, lung, liver, kidney, etc.) failure, malignant tumor, or other unstable condition

  • A history of cerebrovascular disease (if not fully resolved)

  • Photosensitive epilepsy

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Almería Almeria Almería Spain 04120
2 Torrecárdenas University Hospital Almeria Spain 04009
3 San Cecilio University Hospital Granada Spain 18016
4 University of Granada Granada Spain 18071

Sponsors and Collaborators

  • Universidad de Almeria
  • Ministerio de Ciencia e Innovación, Spain
  • European Union

Investigators

  • Principal Investigator: Alberto Soriano-Maldonado, PhD, Universidad de Almeria

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alberto Soriano-Maldonado, PhD, Universidad de Almeria
ClinicalTrials.gov Identifier:
NCT06132399
Other Study ID Numbers:
  • CPP2021-008497
First Posted:
Nov 15, 2023
Last Update Posted:
Nov 15, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Alberto Soriano-Maldonado, PhD, Universidad de Almeria
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 15, 2023